• Molecular NameMethylphenidate
  • Synonymd-methylphenidate HCl; Methyl phenidyl acetate; methylphenidate; Methylphenidate HCl; Methylphenidate hydrochloride; Methylphenidatum [INN-Latin]; Methylphenidylacetate hydrochloride; Metilfenidat hydrochloride; Metilfenidato [INN-Spanish]; Metilfenidato [Italian]; Phenidylate
  • Weight233.311
  • Drugbank_IDDB00422
  • ACS_NO113-45-1
  • Show 3D model
  • LogP (experiment)1.8
  • LogP (predicted, AB/LogP v2.0)2.1
  • pka8.77
  • LogD (pH=7, predicted)0.32
  • Solubility (experiment)1.255mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)0.25
  • LogSw (predicted, AB/LogsW2.0)1.5
  • Sw (mg/ml) (predicted, ACD/Labs)1.7
  • No.of HBond Donors1
  • No.of HBond Acceptors3
  • No.of Rotatable Bonds4
  • TPSA38.33
  • StatusFDA approved
  • AdministrationOral, Transdermal, IV, Nasal
  • PharmacologyA psychostimulant drug approved for treatment of attention-deficit hyperactivity disorder, Postural Orthostatic Tachycardia Syndrome and narcolepsy. It may also be prescribed for off-label use in treatment-resistant cases of lethargy, depression, neural insult, and obesity.
  • Absorption_value80.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability22.0
  • Protein binding15.5
  • Volume of distribution (VD)2.7 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmMethylphenidate and dexmethylphenidate are extensively metabolized, primarily through ester hydrolysis to ritalinic acid.
  • Half life2.4 hours in children and 2.1 hours in adults
  • ExcretionUrine
  • Urinary Excretion1.3
  • Clerance6.7 ml/min/kg
  • ToxicitySymptoms of overdose include vomiting, agitation, tremors, hyperreflexia, muscle twitching, convulsions (may be followed by coma), euphoria, confusion, hallucinations, delirium, sweating, flushing, headache, hyperpyrexia, tachycardia, palpitations, cardiac arrhythmias, hypertension, mydriasis, and dryness of mucous membranes.
  • LD50 (rat)N/A
  • LD50 (mouse)LD50=190mg/kg